Survey and biological insights of pemetrexed-related therapeutic improvement in mesothelioma: The nancy centre of biological resources- mesothelioma cohort

Journal of Thoracic Oncology

Volumn 4, Issue 10, 2009, Pages 1259-1263

  Vlastos, Fotis ^a,b   Hillas, Georgios ^a,b,f   Vidal, Philippe ^a   Lacomme, Stéphanie ^a   Galateau Sallé, Françoise ^c   Vollmer, Ekkehard ^d   Guzman Costabel, Josune ^e   Vignaud, Jean Michel ^a   Martinet, Nadine ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

^c French Mesopath Panel   (France)

^d RESEARCH CENTER BORSTEL   (Germany)

^e RUHR UNIVERSITY BOCHUM   (Germany)

^f NONE   (Greece)

Author keywords

Alleles; Mesothelioma; Pemetrexed; Survival.; Transcobalamin II

Indexed keywords

ASBESTOS; PEMETREXED;

ADULT; ALLELE; ARTICLE; CANCER SURVIVAL; CODON; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FRANCE; GENETIC SUSCEPTIBILITY; GENOTYPE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; PLEURA MESOTHELIOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 70349680979     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181aba6bd     Document Type: Article

References (22)

1. Robinson BWS, Musk AW, Lake AR. Malignant mesothelioma. Lancet 2005;366:397-408.
2. Curran D, Sahmoud T, Therasse P, Van Meerbeeck J, Postmus PE, Giaccone G. Prognostic Factors in Patients With Pleural Mesothelioma: the European Organization for Research and Treatment of Cancer Experience. J Clin Oncol 1998;16:145-152.
3. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mésotheliome and asbestos exposure in the North Western Cape province. Br J Ind Med 1960;17:260-271.
4. Antman KH. Current concepts: malignant mesothelioma. N Engl J Med 1980;303:200-202.
5. Ashcroft T. Epidemiological and quantitative relationships between mesothelioma and asbestos on Tyneside. J Clin Pathol 1973;26:832-840.
6. Nicholson WJ, Perkel G, Selikoff UI. Occupational exposure to asbestos: population at risk and projected mortality: 1980 -2030. Am J Indust Med 1982;3:259-311.
7. Van Meerbeeck JP. Chemotherapy in malignant mesothelioma: what's up, doc? J Thorac Oncol 2006;1:279-280.
8. Tsiouris A, Walesby RK. Malignant pleural mesothelioma: current concepts in treatment. Nat Clin Pract Oncol 2007;4:344-352.
9. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007;6:404-417.
10. Van den Bogaert DP, Pouw EM, van Wijhe G, et al. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thorac Oncol 2006;1:25-30.
11. Jänne PA, Wozniak AJ, Belani CP, et al. Pemetrexed expanded access program investigators. Pemetrexed alone or in combination with cispla-tin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol 2006;1:506-512.
12. Rollins KD, Lindley C. Pemetrexed: a multitargeted antifolate. Clin Ther 2005;27:1343-1382.
13. Kim HN, Kim YK, Lee IK, et al. Association between polymorphisms of folate-metabolizing enzymes and hematological malignancies. Leuk Res 2009;33:82-87.
14. Metintas M, Metintas S, Ak G, et al. Epidemiology of pleural mesothelioma in a population with nonoccupational asbestos exposure. Respirology 2008;13:117-121.
15. Ruffie P, Feld R, Minkin S. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 1989;7:1157-1168.
16. Marinaccio A, Nesti M. Analysis of survival of mesothelioma cases in the Italian register (ReNaM). Eur J Cancer 2003;39:1290-1295.
17. Boutin C, Monnet I, Ruffie P, Astoul P. Mésothéliome malin: tude clinique et thérapeutique. Rev Mal Respir 1999;16:1317-1326. (Pubitemid 30014281)
18. Miller JW, Ramos MI, Garrod MG, Flynn MA, Green R. Transcobal-amin 2 775 G-C polymorphism and indices of vitamin B12 status in healthy older adults. Blood 2002;100:718-720.
19. Alonso-Aperte E, González MP, Póo-Prieto R, Varela-Moreiras G. Folate status and S-adenosylmethionine/S-adenosylhomocysteine ratio in colorectal adenocarcinoma in humans. Eur J Clin Nutr 2008;62:295-298.
20. Hazra A, Wu K, Kraft P, Fuchs CS, Giovannucci EL, Hunter DJ. Twenty four non-synonymous polymorphisms in the one-carbon metabolic pathway and risk of colorectal adenoma in the Nurses' Health Study. Carcinogenesis 2007;28:1510-1519.
21. Zhao R, Gao F, Goldman ID. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem Pharmacol 2001;61:857-865.
22. Zhao R, Zhang S, Hanscom M, Chattopadhyay S, Goldman ID. Loss of reduced folate carrier function and folate depletion results in enhanced pemetrexed inhibition of purine synthesis. Clin Cancer Res 2005;11: 1294-1301.